Previous reports demonstrated that the expression of thrombomodulin (TM) in endothelial cells was modulated by various agents. Although TM was down-regulated by endotoxin or cytokines, up-regulation of TM was accomplished when endothelial cells were stimulated with unphysiologically high concentrations of cyclic AMP derivatives or tumourpromoting phorbol esters. We investigated the expression of TM in human umbilical-vein endothelial cells (HUVECs) by physiological substances that can be released into the bloodstream. Histamine (0.1-10 /tM, 1-48 h) increased TM activity, TM antigen in cell lysates and TM mRNA levels, but 5-hydroxytryptamine and bradykinin had no effect. Enhancement of TM activity by histamine was completely blocked by the Hi-selective antagonist pyrilamine, whereas the H2-antagonist cimetidine had no effect, showing that histamine up-regulates TM activity via Hi-receptors on HUVECs. Enhanced TM activity by histamine and the resultant increase in protein C activation might play a role in a feedback regulation for prevention of vascular thrombosis.
INTRODUCTION
Thrombomodulin (TM), expressed on endothelial cells, is a physiologically important modulator of blood coagulation [1, 2] . TM accelerates thrombin-catalysed protein C activation [3] . Activated protein C is a protease, and with its cofactor protein S [4] acts as an anti-coagulant by inactivating the coagulation factors Va [5] and VIIIa [6] . Recently, TM structure [7, 8] , location {9], regulation of expression [10] [11] [12] [13] and implication as a therapeutic agent [14, 15] have been described. Among these, the regulatory mechanisms for TM expression are important to investigate the modulation of coagulation by endothelial cells. Down-regulation of TM and the accompanying expression of tissue factor occurred on incubation with endotoxin [16] , tumour necrosis factor [ 17] and interleukin-1, [18] in cultured endothelial cells. These results are believed to be analogous to hypercoagulable states frequently resulting in thrombosis and/or disseminated intravascular coagulation in various patients. In contrast, up-regulation of TM activity was observed when the cells were stimulated with tumour-promoting phorbol esters, unphysiologically high concentration of cyclic AMP derivatives, and the adenylate cyclase activator forskolin [13] . Although thrombin and cycloheximide increase TM mRNA levels, they do not increase TM activity in endothelial cells [19] .
In the present studies, we investigate regulation of TM activity by mediators of inflammation. Although several inflammatory cytokines inhibit surface TM activity and induce procoagulant activity of endothelial cells [16] [17] [18] 
EXPERIMENTAL

Materials
Acetylsalicylic acid (aspirin), indomethacin, histamine dihydrochloride, 5-hydroxytryptamine (serotonin) creatinine sulphate complex, bradykinin (acetate salt), cimetidine, pyrilamine (maleate salt), o-phenylenediamine, pig mucosal heparin, human a-thrombin (4000 units/mg of protein), and BSA were purchased from Sigma (St. Louis, MO, U.S.A.). Iscove's modified Dulbecco's medium, fetal-calf serum, penicillin/streptomycin and 0.05 % trypsin/0.02 EDTA in Dulbecco's phosphatebuffered saline (137 mM-NaCl, 3 .67 mM-KCI, 9.66 mM-NaHPO4, 1.72 mM-KH2PO4) were purchased from GIBCO (Grand Island, NY, U.S.A.). Endothelial-cell growth supplement was purchased from Collaborative Research (Belford, MA, U.S.A.). Human protein C was purchased from American Diagnostica (New York, NY, U.S.A.). Human antithrombin III was purchased from Green Cross (Osaka, Japan). The chromogenic substrate S-2366 was purchased from Kabi Vitrum (Stockholm, Sweden). Staurosporine was purchased from Kyowa Medex (Tokyo, Japan). The nick-translation kit was purchased from Boehringer (Mannheim, Germany). The total RNA isolation kit was purchased from Invitrogen (San Diego, CA, U.S.A.). [a-32P]dCTP (6000 Ci/mmol) was purchased from New Research Products (Boston, MA, U.S.A.). A TthlJJI-NheI fragment in the coding region of human TM was kindly provided by Dr. K. Nawa (Research Institute, Daiichi Pharmaceutical Co., Tokyo, Japan) [20] and used as a hybridization probe. cDNA for human , 8-actin was purchased from Wako Pure Chemicals (Osaka, Japan). All other chemicals were reagent-grade products.
Methods
Cell culture. HUVECs were harvested from umbilical-cord veins within 12 h after delivery, by the method of Jaffe et al. [21] . previously reported [13] . All experiments were performed on cells within three passages.
Assay of surface TM activity. Surface TM cofactor activity was determined by using HUVEC monolayers [(1.0-1.5) x 105 cells/ well] in 48-well tissue-culture plates, human thrombin and human protein C by previously reported methods [13, 22] .
Endothelial cells in each well were counted by the method originally described by Drysdale et al. [23] . Cell supernatants from the experimental wells were also stored for measurement. KA-2 or KA-4 anti-(human TM) monoclonal antibodies, whose characteristics were previously reported [24] , were used to determine total TM antigen in cell lysates.
Microtitre plates coated with KA-2 and horseradishperoxidase-conjugated KA-4 were used for e.l.i.s.a. assays. Horseradish peroxidase was conjugated to KA-4 by the method of Nakane & Kawaoi [25] . E.l.i.s.a. assays were performed as previously reported [24] .
Northern blotting. Total cytoplasmic RNA was prepared from confluent HUVECs by methods previously reported [13] . Isolated RNA was analysed by Northern blotting by standard techniques [26] . The probe employed for hybridization was a 32P-labelled 450 bp DNA fragment corresponding to the human TM coding region, nick-translated to a specific radioactivity of > 108 d.p.m./ ,ug. Autoradiograms of Northern blots were prepared as described previously [13] . After washing with distilled water at 65°C for 30 min, the filter was re-hybridized with 32P-labelled cDNA probe for human ,J-actin. After densitometric analysis of autoradiographs. TM mRNA levels were normalized to the concentration of ,1-actin mRNA.
RESULTS
Effects of vasoactive amines on surface TM activity in
HUVECs
The effects of a 4 h exposure to vasoactive amines on surface TM activity was determined ( Fig. 1 (Fig. 3b) , almost parallel to increased surface TM activity (Fig. 3a) . To determine which type of histamine receptor is involved in enhancement of TM activity, HUVECs were co-incubated for 6 of four determinations. Asterisks represent significant differences from the control (*P < 0.05, ***P < 0.001). [27, 28] , the question arose as to whether the enhancement of TM activity by histamine may be due to the actions of PGI2 or other prostanoids. To exclude these possibilities, the effects of histamine on TM activity in HUVECs Vol. 276 pretreated with aspirin or indomethacin, which inhibit cyclooxygenase, were investigated. Aspirin (0.1-1 mM) or indomethacin (1-10 fM) did not abrogate the enhancement of TM activity by histamine, and 1 mM-aspirin even slightly further enhanced the increased TM activity in HUVECs incubated with 100 /M-histamine (Fig. 6) . These results suggested that the enhanced TM activity by histamine is not due to PGI2 or other prostanoids produced by cyclo-oxygenase.
DISCUSSION
Among the vasoactive amines tested, only histamine increased surface TM activity (Fig. 1) resulting from increased TM mRNA levels (Fig. 4) . Histamine released from mast cells in response to various stimuli is known to increase vasopermeability in vivo, and this action of histamine induced oedema, which represents a symptom of inflammation. Killackey et al. [29] reported that histamine increased permeability of microcarrier-cultured endothelial monolayers, and that neither bradykinin nor 5-hydroxytryptamine had any effect. It is possible that bradykinin does not increase permeability by interacting directly with the endothelium, although bradykinin can increase vasopermeability in vivo and has been shown to mediate mast-cell histamine release. Our results suggest that vasoactive amines which directly increase the permeability of endothelial cells may increase surface TM activity.
As shown in Figs. 2 and 3(a) , surface TM activity in HUVECs incubated with 10 /M-histamine increased with time. Total TM antigen in the cell lysates of HUVECs incubated with histamine also increased almost parallel to surface TM activity (Fig. 3) . As we reported previously [13] , dibutyryl cyclic AMP (4-8 h), forskolin (16- treated with dibutyryl cyclic AMP [13] or thrombin [19] . Although the enhancement of TM activity by dibutyryl cyclic AMP is transient (2-8 h) and thrombin decreases surface TM activity in HUVECs, histamine increased both surface TM activity and total TM antigen (Fig. 3) . The increase lasted for various lengths of time, 8-48 h depending on the HUVEC's origin. This is similar to the effect of forskolin [13] . Although forskolin, an activator of adenylate cyclase, increased intracellular cyclic AMP in HUVECs, histamine did not do this (results not shown).
As shown in Fig. 5 , enhancement of TM activity by histamine was blocked by the Hi-selective antagonist pyrilamine, whereas the H2-antagonist cimetidine had no effect, showing that histamine is acting through Hi-receptors. Rotrosen & Gallin [30] reported that H1-receptor occupancy increased endothelial cytosolic Ca2+, decreased F-actin (which indicates endothelial-cell shape change), and promoted albumin diffusion across cultured endothelial monolayers. Activation of Hi-receptors on HUVECs is also involved in stimulation of synthesis and release of PGI2 [27] , synthesis of platelet-activating factor [28] , inositol phosphate accumulation [31] and increase in intracellular Ca2+ [32] . Our results further suggest that histamine is a physiological agonist for endothelial anticoagulant function, although the precise molecular mechanism for increased TM activity is not known. 30 min before addition of histamine, then co-cultured with indomethacin and histamine tor 6 h at 37 'C. HUVECs were then washed and surface TM activity was measured as described in the Experimental section. Asterisks represent significant differences from unstimulated control cells (C) (*P < 0.05, **P < 0.01, ***P < 0.001). Significant differences from surface TM activity of cells incubated with only histamine at the same concentration are indicated by t (P < 0.05).
Since PGI2 release has been associated with increased release of cyclic AMP [33] , and derivatives of cyclic AMP up-regulate TM in HUVECs [13] , mouse embryonal carcinoma cells [34, 35] , and megakaryoblastic leukaemia cells (K. Ohashi, K. Hirokawa, N. Komatsu & N. Aoki, unpublished work), PGI2 released by histamine and the subsequent increase in intracellular cyclic AMP may be a causal factor in up-regulation of TM. However, pretreatment of HUVECs with aspirin or indomethacin did not abrogate enhancement of TM activity by histamine, as shown in Fig. 6 , although those pretreatments were reported to inhibit PGI2 release from HUVECs [33] . In addition, histamine did not increase intracellular cyclic AMP in HUVECs, whereas forskolin increased the levels (results not shown). Hence we exclude the possibility that the enhancement of TM activity by histamine was due to increased intracellular cyclic AMP levels induced by PGI2 released from endothelial cells. Johnson et al. [36] reported that histamine increased the release of not only prostaglandins (PGI2, Histamine has been shown to promote hydrolysis of phosphatidylinositol 4,5-bisphosphate and to increase cytosolic Ca2l in populations of endothelial cells [32] . Hydrolysis of phosphatidylinositol 4,5-bisphosphate generates inositol phosphate, which increases cytosolic Ca2+, and a natural activator of protein kinase C, diacylglycerol [37] . As reported previously [13] , a potent activator of protein kinase C, phorbol myristate acetate, increased TM activity h) and TM mRNA levels (4-40 h; maximum at 24 h) in HUVECs after a transient decrease in TM activity (0.5-16 h). Up-regulation of TM by histamine occurred at earlier time points than that by phorbol esters, and was not preceded by a transient decrease in TM activity (Figs. 2, 3a, 4) . In addition, enhancement of TM activity by histamine was not abrogated by an inhibitor of protein kinase C, staurosporine, and the intracellular Ca2+ antagonist TMB-8 did not affect the increase in TM activity by histamine, whereas the Ca2+ ionophore A23187 decreased TM activity (results not shown). Hence we could not attribute up-regulation of TM exclusively to activation of protein kinase C or increased cytosolic Ca2l.
Although it was reported that histamine augmented endothelial-cell proliferation [38, 39] , histamine-increased TM mRNA levels was not a result of a general activation of the cells, since all values were normalized to /3-actin mRNA. The concentration of histamine used in the present study is not unphysiologically high, since plasma histamine at the time of an episode of ventricular fibrillation in a patient after the induction of anaesthesia was observed to be 10 ng/ml (approx. 0.6 ftM), although normal histamine levels are less than 1 ng/ml (5 nM) [401. At sites of inflammation, the local concentration of histamine may be higher than those values and might reach the levels used in the present experiments. Thus we conclude that histamine may have a role in regulation of coagulation via the modulation of endothelial functions.
Histamine increases endothelial anticoagulant activities by increasing TM activity, synthesis and release of PGI2 [27, 28] or endothelial-cell-derived relaxing factor ('EDRF') [41] , and simultaneously increases endothelial procoagulant activities by increasing synthesis of platelet-activating factor [28] , synthesis of tissue factor [42] , and the release of von Willebrand factor [43] . Thus histamine is a bidirectional agonist for regulation of coagulation through its effects on endothelial cells.
